Form 8-K

8-K — Humacyte, Inc.

Accession: 0001104659-26-094440

Filed: 2026-08-12

Period: 2026-08-12

CIK: 0001818382

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Results of Operations and Financial Condition

Item: Financial Statements and Exhibits

Documents

8-K — tm2622949d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2622949d1_ex99-1.htm)

GRAPHIC (tm2622949d1_ex99-1img001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2622949d1_8k.htm · Sequence: 1

false

0001818382

2026-08-12

0001818382

us-gaap:CommonStockMember

2026-08-12

0001818382

HUMA:RedeemableWarrantsEachWholeWarrantExercisableForOneOfCommonAtExercisePriceOf11.50Member

2026-08-12

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange

Act of 1934

Date of Report (Date of earliest event reported):

August 12, 2026

Humacyte, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39532

85-1763759

(State or other jurisdiction of

incorporation or organization)

(Commission File Number)

(I.R.S. Employer

Identification Number)

2525 East North Carolina Highway 54

Durham, NC

27713

(Address of principal executive offices)

(Zip code)

(919) 313-9633

(Registrant’s telephone number, including

area code)

Not Applicable

(Former name or former address, if changed since

last report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each

exchange on which

registered

Common

Stock, par value $0.0001 per share

HUMA

The Nasdaq Stock Market LLC

Redeemable

Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50

HUMAW

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period

for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial Condition

On August 12, 2026, Humacyte, Inc. issued a press

release regarding its financial results for its fiscal second quarter ended June 30, 2026. A copy of this press release is furnished as

Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information contained herein, including the

exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as

amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or

the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number

Description

99.1

Press release, dated August 12, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HUMACYTE, INC.

Date: August 12, 2026

By:

/s/ Dale A. Sander

Name:

Dale A. Sander

Title:

Chief Financial Officer, Chief Corporate Development Officer and Treasurer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2622949d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Humacyte

Announces Second Quarter 2026 Financial Results and Provides Business Update

– Breakthrough results from V012 dialysis

access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis

access to be filed with the Food and Drug Administration (FDA) during the second half of 2026 –

– FDA accepted IND for first-in-human

clinical study of CTEV for CABG with Phase 2a study expected to start Q3 2026 –

– Second quarter sales of Symvess®

were $0.4 million in 2026 compared to $0.1 million in 2025 –

– Conference call today at 8:00 am ET

–

DURHAM,

N.C., August 12, 2026 – Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally

implantable, bioengineered human tissues at commercial scale, today announced financial results for the second quarter ended June

30, 2026 and provided a business update.

“Our second quarter and recent weeks have

been a transformative period for Humacyte and our pipeline expansion, led by the presentation of breakthrough top-line interim results

from our V012 Phase 3 trial in female dialysis access patients at the Society of Vascular Surgery’s (SVS) Vascular Annual Meeting

(VAM) in Boston,” said Laura Niklason, M.D., Ph.D., Founder and Chief Executive Officer of Humacyte. “Results from this

trial exceeded our expectations, and our acellular tissue engineered vessel (ATEV) outperformed autologous arteriovenous (AV) fistula,

the current standard of care for patients on dialysis. We look forward to using this data to file a supplemental BLA with the FDA later

this year. We are also pleased that the FDA recently accepted our Investigational New Drug (IND) application for our coronary tissue engineered

vessel (CTEV), and plan to initiate a Phase 2a study in coronary artery bypass grafting (CABG) during the third quarter. No new off-the-shelf

conduits have been introduced for CABG in the past 40 years, and our preclinical results suggest that the CTEV may be a promising off-the-shelf

alternative to saphenous vein grafts in CABG.”

The Company’s operational progress was highlighted

by Jim Mercadante, Humacyte’s recently appointed Chief Commercial Officer, who said, “We intentionally focused our second

quarter on rebuilding our commercial effort for Symvess, along with implementing an enterprise-wide transformation. Our goal was to drive

hospital product adoption and product usage, and to better position Humacyte for sustained growth.” He then addressed the Company’s

evolution, “We have remodeled our commercial team to ensure members have relevant longstanding relationships in the vascular surgery

space. Beyond team capabilities, we have refined introductory pricing incentive programs, professional-to-professional education, and

streamlined our value analysis committee process to drive Symvess adoption. These combined initiatives are creating a growth platform

to drive approvals, utilization and revenue growth for this category-defining product. As we move into the second half of 2026, we are

already seeing results from this approach with influential hospitals adopting Symvess and utilization strengthening across the board.”

Second Quarter 2026 and Recent Corporate Highlights

Breakthrough Phase 3 Results of ATEV in Dialysis Support Planned

BLA Filing

· Superior Results Reported from V012 Phase

3 Study in Women: In June 2026, breakthrough results from the V012 Phase 3 trial in female dialysis patients were presented at the

Society for Vascular Surgery's Vascular Annual Meeting. In a pre-specified interim analysis of the first 80 patients from the study,

the ATEV was observed to outperform AV fistula, the current standard of care, significantly reducing usage of infection-prone catheters.

Women who received the ATEV achieved an average of 91 more catheter-free days than those receiving AV fistula and the difference was statistically

significant (p=0.00070), meeting the primary efficacy endpoint of the study. Infections were also less common in patients receiving the

ATEV, and patients receiving the ATEV had 6 infections per 100 patient years compared with 23 per 100 patient years for patients who received

an AV fistula. Women experience up to two times the rate of fistula maturation failure compared to men, leaving many reliant on infection-prone

catheters. The V012 study, focused on female dialysis patients, demonstrates that a biologic conduit has the potential to address this

longstanding disparity.

· Planned BLA Filing: The above V012 results,

combined with results from the V007 Phase 3 trial reported previously, suggest that the ATEV could represent the first major advance in

dialysis access in decades, offering surgeons an alternative option for patients whose risk factors make AV fistula maturation difficult.

Based on these results, Humacyte plans to submit a supplemental Biologics License Application to the FDA in the second half of 2026.

· Appointed Key Nephrologists as Advisors to

Prepare for Planned Dialysis Commercialization: Robert J. (Rob) Kossmann, MD, FACP, FASN and Prabir Roy-Chaudhury, MD, PhD, FASN have

been appointed as advisors to Humacyte. These leading nephrologists will help prepare for the planned commercialization of the ATEV in

dialysis access, if approved by the FDA, contribute to the development of health economic, reimbursement and market access strategies

as well as provide peer-to-peer scientific support and medical education.

· Virtual KOL Event Highlights Need for ATEV

in AV Access: The April 2026 event featured Prabir Roy-Chaudhury MD, PhD, FASN (University of North Carolina (UNC) Kidney Center,

Salisbury VA Medical Center), and Mohamad A. Hussain, MD, PhD, RPVI, FAHA, FRCSC, FACS (Brigham & Women's Hospital, Center for Surgery

and Public Health, Harvard Medical School), who joined Humacyte management to discuss the unmet need and current surgical access landscape

for the nearly 500,000 U.S. patients currently on dialysis.

First Human Study in CABG

· Coronary Tissue Engineered Vessel (CTEV) Progresses

Toward First Human Study: The FDA has accepted the IND application for a first-in-human clinical study of the CTEV in coronary artery

bypass grafting. Humacyte plans to initiate a Phase 2a study of the CTEV in CABG patients during the current quarter. To support this

planned study, Humacyte has completed the first large-scale manufacturing lot of CTEV in its commercial-scale production facilities.

Symvess U.S. and International Commercialization

· Appointed Industry Veteran James Mercadante

as Chief Commercial Officer: Mr. Mercadante is a seasoned commercial executive with a track record of successful leadership across

medical devices, diagnostics, and healthcare technology. Over his career, he and his teams have launched over 50 new products and delivered

millions of dollars in growth for multiple technologies, including high-end peripheral vascular and aortic devices. Mr. Mercadante is

overseeing all aspects of the Company's commercial strategy, including sales, marketing, and market access, as Humacyte continues to expand

the U.S. launch of Symvess and prepares for potential future commercial indications.

· Appointed Renowned Vascular Surgeon Dr. Todd

E. Rasmussen as Chief Surgical Officer: Dr. Rasmussen joined Humacyte with extensive expertise as a vascular surgeon, including a

28-year career in the U.S. Air Force during which he deployed multiple times during the Iraq and Afghanistan Wars. A recognized leader

in peripheral vascular surgery and trauma repair, at Humacyte he is focusing on providing professional-to-professional scientific support,

medical education, and technical insights to surgeons and other healthcare providers. He brings an experienced surgical perspective and

leadership to the development of education and clinical support materials aligned with regulatory guidance to optimize the safe, appropriate,

and effective implantation of Humacyte products.

· Marketing Authorization Application for Symvess

in Israel Accepted for Review: The Company’s Marketing Authorization Application (MAA) for approval of Symvess for arterial

injury repair was accepted for review by the Israel Ministry of Health in April 2026. The Ministry of Health set a 180-working-day review

period for the MAA due to the existing FDA approval of Symvess in extremity vascular injury.

· New U.S. Department of Defense Funding for

Procurement of Bioengineered Blood Vessels: The FY 2026 U.S. Department of Defense Appropriations Act includes dedicated funding to

support the evaluation and incorporation of biologic vascular repair technologies for the warfighters suffering from traumatic vascular

injuries. The Company is working with leaders in the military and the Pentagon to ensure that American service personnel will have access

to Symvess.

Corporate Update

· Public Offering: In June 2026 Humacyte

raised aggregate gross proceeds of $57.5 million from a public offering of its common stock. Humacyte intends to use the net proceeds

from the offering to fund the commercialization of Symvess, the planned filing of a Biologics License Application supplement in a dialysis

indication, and related activities, the development of the product candidates in its pipeline, and for working capital and general corporate

purposes.

· Cost Reduction: In May 2026, Humacyte

implemented a restructuring of its workforce to reduce total headcount by approximately 45 employees through a reduction in force and

by deferment of planned hires. Humacyte estimates net savings due to the workforce reductions and operating cost reductions, net of termination

severance and benefits, totaling approximately $14.3 million during 2026.

For uses other than the FDA approval in the extremity

vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory

agency. The CTEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Second Quarter 2026 Financial Highlights

· Commercial sales of Symvess were $0.4 million in the second quarter of 2026

compared to $0.1 million in the second quarter of 2025. For the six months ended June 30 2026, commercial sales of Symvess were $0.9 million

compared to $0.2 million for the six months ended June 30, 2025. There was no meaningful contract revenue in either the three or six months

ended June 30, 2026 due to completion of a research collaboration project in the prior year, compared to $0.2 million and $0.6 million

for the three and six months ended June 30, 2025, respectively.

· Cost of goods sold was $1.2 million for the second quarter of 2026 compared

to $0.2 million for the second quarter of 2025. In the second quarter of 2026, $0.2 million of cost of goods sold related to the cost

of units recorded as sales revenue during the period, and the remainder was primarily comprised of a $0.7 million inventory reserve recorded

to reduce certain inventory balances to their estimated net realizable value, as well as overhead related to unused production capacity

which was recorded as an expense in the period. Cost of goods sold was $3.3 million for the six months ended June 30, 2026 compared to

$0.4 million for the six months ended June 30, 2025. During the six months ended June 30, 2026, $0.5 million of cost of goods sold related

to the cost of units recorded as sales revenue during the period, and the remainder was primarily comprised of a $2.3 million inventory

reserve and expenses related to unused production capacity.

· Research and development expenses for the three months and six months of

2026 were $18.1 million and $37.6 million, respectively, compared to $22.0 million and $37.4 million for the same periods in 2025. The

decrease in research and development expenses during the second quarter of 2026 was primarily due to a reduction in non-commercial manufacturing

runs and reduced clinical trial expenses.

· General and administrative expenses were $8.0 million and $16.0 million for

the three months and six months ended June 30, 2026, respectively, consistent with the $7.8 million and $16.0 million for the same periods

in 2025.

· Other net income (expense) was net expense of $9.8 million and net income

of $1.5 million for the three months and six months ended June 30, 2026, respectively, compared to net expense of $7.9 million for the

three months ended June 30, 2025 and other net income of $54.4 million for the six months ended June 30, 2025. The increase in other net

expense for the three months ended June 30, 2026 and the decrease in other net income for the six months ended June 30, 2026 compared

to the prior year periods resulted primarily from the non-cash remeasurement of the contingent earnout liability and other derivative

liabilities.

· Net loss was $36.8 million and $54.4 million for the three months and six

months ended June 30, 2026, respectively, compared to a net loss of $37.7 million for the three months ended June 30, 2025 and net income

of $1.5 million for the six months ended June 30, 2025. The increase in net loss for the six months ended June 30, 2026 compared to the

prior year period was primarily due to the non-cash remeasurement of the contingent earnout liability described above.

· The Company had cash, cash equivalents and restricted cash of $80.3 million

as of June 30, 2026. Total net cash provided was $29.4 million for the first six months of 2026, compared to total net cash used of $6.9

million for the first six months of 2025. The increase in total net cash provided for the six months ended June 30, 2026 resulted from

higher proceeds from sales of common stock and a reduction in net cash used in operations.

Conference Call and Webcast Details

Title:

Humacyte Second Quarter 2026 Financial Results and Corporate Update

Date:

August 12, 2026

Time:

8:00 AM Eastern Time

Conference Call Details:

1-877-704-4453 (U.S. Investors Dial)

1-201-389-0920 (International Investors Dial)

13761781 (Conference ID)

Call meTM Feature:

Click

Here

Webcast:

Click

Here

A replay of the webcast will be available following the conclusion

of the live broadcast and will be accessible on the investors section of the Company’s website for at least 30 days.

INDICATION

Symvess is an acellular tissue engineered vessel indicated for use

in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and

autologous vein graft is not feasible.

IMPORTANT SAFETY INFORMATION

BOXED WARNING: GRAFT FAILURE

Loss of Symvess integrity due to mid-graft rupture or anastomotic failure

can result in life threatening hemorrhage.

CONTRAINDICATIONS

DO NOT use Symvess in patients who have a medical condition that would

preclude long-term antiplatelet therapy (such as aspirin or clopidogrel) after resolution of acute injuries.

WARNINGS AND PRECAUTIONS

· Graft Rupture

Vascular graft rupture has occurred in patients treated with Symvess.

Advise patients that arterial bleeding can be life-threatening and to seek emergent medical evaluation for any signs or symptoms of graft

rupture such as bleeding, pain and swelling in the extremity, or signs of extremity ischemia.

· Anastomotic Failure

Anastomotic failure has occurred in patients treated with Symvess.

In clinical studies of Symvess, anastomotic failure occurred within the first 36 days post-implantation. Monitor patients for signs of

anastomotic failure such as pain and swelling at the surgical site, decreasing hemoglobin or other signs and symptoms of bleeding. Advise

patients to seek urgent medical evaluation if they have any signs or symptoms that may be indicative of anastomotic failure such as bleeding,

swelling or worsening pain at the surgical site or changes in color of overlying skin.

· Thrombosis

Thrombosis has occurred in patients treated with Symvess. In clinical

trials of Symvess, patients received antiplatelet therapy following implantation of Symvess to reduce the risk of thrombosis. The risk

of thrombosis may increase in patients who discontinue antiplatelet therapy. Anti-platelet therapy is recommended following treatment

with Symvess.

· Transmission of Infectious Diseases

Symvess is manufactured using cells and reagents that may transmit

infectious diseases or infectious agents. The cells used in the manufacture of Symvess are derived from a donor who met the donor eligibility

requirements for transmissible infectious diseases which includes screening and testing of risks associated with human immunodeficiency

virus 1 (HIV-1), human immunodeficiency virus 2 (HIV-2), hepatitis B virus (HBV), hepatitis C virus (HCV), and syphilis (Treponema pallidum).

The cell banks are tested negative for human and animal viruses, retroviruses, bacteria, fungi, yeast, and mycoplasma. While all animal-derived

reagents are tested for animal viruses, bacteria, fungi, and mycoplasma before use, these measures do not eliminate the risk of transmitting

these or other transmissible infectious diseases and disease agents. Fetal bovine serum is sourced to minimize the risk of transmitting

a prion protein that causes bovine spongiform encephalopathy and the cause of a rare fatal condition in humans called variant Creutzfeldt-Jakob

disease. No transmissible agent infections have been reported during clinical testing.

ADVERSE REACTIONS

The most common adverse reactions (occurring at ≥ 10%), were vascular

graft thrombosis, pyrexia (fever) and pain.

Please see full Prescribing Information at www.symvess.com,

including Boxed Warning, for Symvess.

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology

platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve

the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide

range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered

vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical

trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD).

Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and

multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate

to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation.

Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT

designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more

information, visit www.Humacyte.com.

Forward-Looking Statements

This press release contains forward-looking statements that are based

on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following

words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,”

“plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,”

“potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology,

although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that

may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or

implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained

in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and

our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not

limited to, our plans and ability to commercialize Symvess and, if approved by regulatory authorities, our product candidates, successfully

and on our anticipated timelines; the degree of market acceptance of and the availability of third-party coverage and reimbursement for

Symvess and, if approved by regulatory authorities, our product candidates; our ability to manufacture Symvess and, if approved by regulatory

authorities, our product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; the anticipated benefits

of our ATEVs relative to existing alternatives; our plans and ability to execute product development, process development and preclinical

development efforts successfully and on our anticipated timelines; our ability to design, initiate and successfully complete clinical

trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials; the

anticipated characteristics and performance of our ATEVs; the implementation of our business model and strategic plans for our business;

our ability to execute and achieve the expected benefits of our cost-saving measures and whether our efforts will result in further actions

or additional asset impairment charges that adversely affect our business; the timing and expected benefits of the commitment to purchase

Symvess to facilitate a clinical evaluation and outreach program in the KSA; our ability to realize the benefits of the DoD’s funding

in the DoD Appropriations Act; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that

the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number

of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others,

changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, and/or

competitive factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual

Report on Form 10-K for the year ended December 31, 2025 and Form 10-Q for the quarter ended March 31, 2026, each filed by Humacyte with

the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore,

if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in

these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that

we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention

of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements

as representing our views as of any date subsequent to the date of this press release.

Humacyte Investor Contact:

Joyce Allaire

LifeSci Advisors LLC

+1-617-435-6602

jallaire@lifesciadvisors.com

investors@humacyte.com

Humacyte Media Contact:

Rich Luchette

Precision Strategies

+1-202-845-3924

rich@precisionstrategies.com

media@humacyte.com

Humacyte, Inc.

Condensed Consolidated Statements

of Operations and Comprehensive Income (Loss)

(unaudited)

(in thousands except for share

and per share amounts)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Revenue:

Product revenue, net

$ 406

$ 100

$ 899

$ 247

Contract revenue

—

201

571

Total revenue

406

301

901

818

Operating expenses:

Cost of goods sold

1,231

213

3,269

360

Research and development

18,144

22,006

37,606

37,424

General and administrative

8,027

7,809

15,957

15,945

Total operating expenses

27,402

30,028

56,832

53,729

Loss from operations

(26,996 )

(29,727 )

(55,931 )

(52,911

Other (expense) income, net:

Change in fair value of contingent earnout liability

(2,718 )

(5,470 )

2,014

44,261

Other (expense) income, net

(7,088 )

(2,461 )

(504 )

10,131

Total other (expense) income, net

(9,806 )

(7,931 )

1,510

54,392

Net (loss) income and comprehensive (loss) income

$ (36,802 )

$ (37,658 )

$ (54,421 )

$ 1,481

Net (loss) income per share, basic

$ (0.16 )

$ (0.24 )

$ (0.25 )

$ 0.01

Weighted-average shares outstanding, basic

234,182,284

155,437,281

216,114,910

143,533,212

Net (loss) income per share, diluted

$ (0.16 )

$ (0.24 )

$ (0.25 )

$ 0.01

Weighted-average shares outstanding, diluted

234,182,284

155,437,281

216,114,910

143,664,424

Humacyte, Inc.

Condensed Consolidated Balance

Sheets

(unaudited)

(in thousands)

June 30,

December 31,

2026

2025

Assets

Current assets:

Cash and cash equivalents

$ 79,903

$ 50,497

Inventory, net

6,985

13,589

Prepaid expenses and other current assets

5,899

3,709

Total current assets

92,787

67,795

Restricted cash

209

Property and equipment, net

16,170

18,544

Finance lease right-of-use assets, net

28,249

29,146

Other long-term assets

672

Total assets

$ 138,087

$ 116,366

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable

$ 4,157

$ 5,404

Accrued expenses

9,273

10,540

Other current liabilities

1,518

2,428

Total current liabilities

14,948

18,372

Long-term debt

36,324

35,444

Contingent Earnout Liability

9,478

11,492

Common stock warrant liabilities

15,651

19,392

Finance lease obligation, net of current portion

28,338

26,974

Other long-term liabilities

2,087

1,583

Total liabilities

106,826

113,257

Stockholders' equity:

Common stock and additional paid-in capital

812,530

729,957

Accumulated deficit

(781,269 )

(726,848 )

Total stockholders' equity

31,261

3,109

Total liabilities and stockholders' equity

$ 138,087

$ 116,366

GRAPHIC

Filename: tm2622949d1_ex99-1img001.jpg · Sequence: 7

Binary file (6509 bytes)

Download tm2622949d1_ex99-1img001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 9

v3.26.1

Cover

Aug. 12, 2026

Document Information [Line Items]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 12, 2026

Entity File Number

001-39532

Entity Registrant Name

Humacyte, Inc.

Entity Central Index Key

0001818382

Entity Tax Identification Number

85-1763759

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2525 East North Carolina Highway 54

Entity Address, City or Town

Durham

Entity Address, State or Province

Entity Address, Postal Zip Code

27713

City Area Code

919

Local Phone Number

313-9633

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

Common Stock [Member]

Document Information [Line Items]

Title of 12(b) Security

Common

Stock, par value $0.0001 per share

Trading Symbol

HUMA

Security Exchange Name

NASDAQ

Redeemable Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 [Member]

Document Information [Line Items]

Title of 12(b) Security

Redeemable

Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50

Trading Symbol

HUMAW

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:

dei_DocumentInformationLineItems

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=HUMA_RedeemableWarrantsEachWholeWarrantExercisableForOneOfCommonAtExercisePriceOf11.50Member

Namespace Prefix:

Data Type:

Balance Type:

Period Type: